Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis?
Autore:
Wang, LW; Fu, XL; Clough, R; Sibley, G; Fan, M; Bentel, GC; Marks, LB; Anscher, MS;
Indirizzi:
Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA Duke Univ Durham NC USA 27710 tr, Dept Radiat Oncol, Durham, NC 27710 USA
Titolo Testata:
RADIATION RESEARCH
fascicolo: 4, volume: 153, anno: 2000,
pagine: 405 - 410
SICI:
0033-7587(200004)153:4<405:CAEIPA>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR-BETA; PULMONARY ENDOTHELIAL DYSFUNCTION; RNA ENCODING PROCOLLAGENS; DOSE-VOLUME HISTOGRAM; LUNG-CANCER; TRANSFORMING GROWTH-FACTOR-BETA-1; BREAST-CANCER; NORMAL TISSUE; II RECEPTOR; TGF-BETA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
42
Recensione:
Indirizzi per estratti:
Indirizzo: Anscher, MS Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA Duke Univ Durham NC USA 27710 iat Oncol, Durham, NC 27710 USA
Citazione:
L.W. Wang et al., "Can angiotensin-converting enzyme inhibitors protect against symptomatic radiation pneumonitis?", RADIAT RES, 153(4), 2000, pp. 405-410

Abstract

This study was designed to determine whether patients taking angiotensin-converting enzyme (ACE) inhibitors while receiving radiation therapy for lung cancer are protected from developing symptomatic radiation pneumonitis, The records of 213 eligible patients receiving thoracic irradiation for lungcancer with curative intent at Duke University Medical Center from 1994-1997 were reviewed. Of the 213 patients, 26 (12.2%) were on ACE inhibitors (usually for the management of hypertension) during radiotherapy (group 1); the remaining 187 patients (group 2) were not. Patients were irradiated, with fields shaped to protect normal tissues, with total doses of 50-80 Gy. After treatment, patients were generally followed every 3 months for 2 years,then every 6 months thereafter. Symptomatic radiation pneumonitis was scored according to modified National Cancer Institute Common Toxicity Criteria(i.e., radiographic changes alone were not sufficient for the diagnosis ofpneumonitis). There was no difference in the incidence of pneumonitis between the two groups (P = 0.75). Fifteen percent of the patients on ACE inhibitors (group 1) developed symptomatic radiation-induced lung injury compared to 12% of the patients not receiving these drugs (group 2). Although patients in group 1 tended to develop pneumonitis slightly sooner than did patients in group 2, this difference also was not significant (P = 0.8). Withinthe dose range prescribed for treating hypertension, ACE inhibitors do notappear to either decrease the incidence or delay the onset of symptomatic radiation pneumonitis among lung cancer patients receiving thoracic irradiation. (C) 2000 by Radiation Research Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/11/20 alle ore 14:19:36